# A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

> **NCT02623972** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 22 (actual)

## Conditions studied

- Inflammatory Breast Cancer
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

## Interventions

- **DRUG:** Eribulin
- **DRUG:** Adriamycin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02623972
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-02-26
- **Primary completion:** 2021-05
- **Final completion:** 2026-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02623972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02623972, "A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02623972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*